Head to Head Analysis: VolitionRx (NYSE:VNRX) vs. Intellia Therapeutics (NASDAQ:NTLA) – Defense World

Intellia Therapeutics (NASDAQ:NTLA Get Rating) and VolitionRx (NYSE:VNRX Get Rating) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations.

This is a summary of recent ratings and recommmendations for Intellia Therapeutics and VolitionRx, as reported by MarketBeat.

Intellia Therapeutics currently has a consensus target price of $128.00, suggesting a potential upside of 88.96%. Given Intellia Therapeutics higher probable upside, equities research analysts clearly believe Intellia Therapeutics is more favorable than VolitionRx.

This table compares Intellia Therapeutics and VolitionRxs net margins, return on equity and return on assets.

This table compares Intellia Therapeutics and VolitionRxs gross revenue, earnings per share (EPS) and valuation.

VolitionRx has lower revenue, but higher earnings than Intellia Therapeutics. Intellia Therapeutics is trading at a lower price-to-earnings ratio than VolitionRx, indicating that it is currently the more affordable of the two stocks.

Intellia Therapeutics has a beta of 2, indicating that its stock price is 100% more volatile than the S&P 500. Comparatively, VolitionRx has a beta of 1.62, indicating that its stock price is 62% more volatile than the S&P 500.

Intellia Therapeutics beats VolitionRx on 8 of the 13 factors compared between the two stocks.

(Get Rating)

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

(Get Rating)

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company operates Nucleosomics a technology platform for blood test. VolitionRx Limited is based in Austin, Texas.

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

See the original post here:
Head to Head Analysis: VolitionRx (NYSE:VNRX) vs. Intellia Therapeutics (NASDAQ:NTLA) - Defense World